Evidence map›Paper›PMID 41732853›Full record

ArticleCirculation. Heart failure2026

Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With Transthyretin and Light Chain Cardiac Amyloidosis.

Mattia Zampieri, Giulia Biagioni, Annamaria Del Franco, Marco Canepa, Italo Porto, Margherita Zanoletti, Marianna Eleonora Labate, Aldostefano Porcari, Luca Bordignon, Marco Merlo and 17 more

Abstract readComparative Study
In one paragraph

Article in Circulation. Heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Mattia Zampieri *Department of Clinical and Experimental Medicine, Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy (M. Zampieri, G.B., A.D.F., V.F., A.A., C.M., C.F., F.P., F.C.).ORCID 0000-0002-1140-134X
Giulia Biagioni *Department of Clinical and Experimental Medicine, Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy (M. Zampieri, G.B., A.D.F., V.F., A.A., C.M., C.F., F.P., F.C.).
Annamaria Del FrancoDepartment of Clinical and Experimental Medicine, Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy (M. Zampieri, G.B., A.D.F., V.F., A.A., C.M., C.F., F.P., F.C.).ORCID 0000-0003-1405-9436
Marco CanepaCardiology Unit, Ospedale Policlinico San Martino IRCCS, Genoa, Italy (M.C., I.P., M.E.L.).ORCID 0000-0001-9063-5576
Italo PortoCardiology Unit, Ospedale Policlinico San Martino IRCCS, Genoa, Italy (M.C., I.P., M.E.L.).ORCID 0000-0002-9854-5046
Margherita ZanolettiDepartment of Internal Medicine, University of Genova, Italy (M.C., I.P., M. Zanoletti).ORCID 0009-0001-4379-4870
Marianna Eleonora LabateCardiology Unit, Ospedale Policlinico San Martino IRCCS, Genoa, Italy (M.C., I.P., M.E.L.).
Aldostefano PorcariCardiovascular Department, Centre for Diagnosis and Treatment of Cardiomyopathies, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Italy (A. Porcari, L.B., M.M., G. Sinagra).ORCID 0000-0003-3307-0825
Luca BordignonCardiovascular Department, Centre for Diagnosis and Treatment of Cardiomyopathies, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Italy (A. Porcari, L.B., M.M., G. Sinagra).
Marco MerloCardiovascular Department, Centre for Diagnosis and Treatment of Cardiomyopathies, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Italy (A. Porcari, L.B., M.M., G. Sinagra).ORCID 0000-0002-1022-3131
Gianfranco SinagraCardiovascular Department, Centre for Diagnosis and Treatment of Cardiomyopathies, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Italy (A. Porcari, L.B., M.M., G. Sinagra).ORCID 0000-0003-2700-8478
Giacomo TiniDipartimento di Medicina Clinica e Molecolare, Sapienza Università di Roma, Italy (G.T., B.M., E. Barbato).ORCID 0000-0001-8520-152X
Beatrice MusumeciDipartimento di Medicina Clinica e Molecolare, Sapienza Università di Roma, Italy (G.T., B.M., E. Barbato).ORCID 0000-0003-4872-7981
Emanuele BarbatoDipartimento di Medicina Clinica e Molecolare, Sapienza Università di Roma, Italy (G.T., B.M., E. Barbato).ORCID 0000-0002-0050-5178
Camillo AutoreSan Raffaele Cassino, Frosinone, Italy (C.A.).ORCID 0000-0002-6542-7342
Elena BiaginiEuropean Reference Network for rare, low prevalence and complex diseases of the heart (ERN GUARD-Heart) (A. Porcari, L.B., M.M., G. Sinagra, E. Biagini, S.L.).ORCID 0000-0003-0295-0440
Simone LonghiEuropean Reference Network for rare, low prevalence and complex diseases of the heart (ERN GUARD-Heart) (A. Porcari, L.B., M.M., G. Sinagra, E. Biagini, S.L.).ORCID 0000-0002-7512-1179
Giuseppe SenaCardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliero- Universitaria di Bologna, Italy (E. Biagini, S.L., G. Sena, A. Ponziani, G. Saturi).ORCID 0009-0009-6469-3786
Alberto PonzianiCardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliero- Universitaria di Bologna, Italy (E. Biagini, S.L., G. Sena, A. Ponziani, G. Saturi).ORCID 0000-0001-5090-265X
Giulia SaturiCardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliero- Universitaria di Bologna, Italy (E. Biagini, S.L., G. Sena, A. Ponziani, G. Saturi).ORCID 0000-0002-8154-3538
Vera FicoDepartment of Clinical and Experimental Medicine, Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy (M. Zampieri, G.B., A.D.F., V.F., A.A., C.M., C.F., F.P., F.C.).ORCID 0009-0006-6149-7278
Alessia ArgiròDepartment of Clinical and Experimental Medicine, Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy (M. Zampieri, G.B., A.D.F., V.F., A.A., C.M., C.F., F.P., F.C.).ORCID 0000-0002-6394-9948
Carlotta MazzoniDepartment of Clinical and Experimental Medicine, Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy (M. Zampieri, G.B., A.D.F., V.F., A.A., C.M., C.F., F.P., F.C.).ORCID 0000-0003-1330-7223
Carlo FumagalliDepartment of Clinical and Experimental Medicine, Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy (M. Zampieri, G.B., A.D.F., V.F., A.A., C.M., C.F., F.P., F.C.).ORCID 0000-0001-7963-5049
Iacopo OlivottoCardiomyopathy Unit, Careggi University Hospital, Florence, Italy (M. Zampieri, G.B., A.D.F., V.F., A.A., C.M., C.F., I.O., F.C.).ORCID 0000-0003-1751-9266
Federico PerfettoDepartment of Clinical and Experimental Medicine, Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy (M. Zampieri, G.B., A.D.F., V.F., A.A., C.M., C.F., F.P., F.C.).ORCID 0000-0003-0276-8331
Francesco CappelliDepartment of Clinical and Experimental Medicine, Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy (M. Zampieri, G.B., A.D.F., V.F., A.A., C.M., C.F., F.P., F.C.).ORCID 0000-0002-1622-0732

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe tenet of cardiac amyloidosis (CA) as a paradigm of heart failure with restrictive ventricular physiology and preserved systolic function has come under scrutiny. We aimed to evaluate the prevalence and clinical significance of left ventricular (LV) systolic dysfunction versus restriction in a large real-world cohort with CA, assessed at the time of diagnosis.

methodsWe retrospectively analyzed 540 TTR (transthyretin)-CA and 280 AL (light chain)-CA. Patients were divided into 3 LV phenotypes: (1) preserved LV function: LV ejection fraction >40% associated with grade I diastolic dysfunction; (2) restriction: LV ejection fraction >40% associated with grade II/III diastolic dysfunction; (3) systolic dysfunction: LV ejection fraction ≤40% irrespective of diastolic function. We analyzed the progression from preserved LV function towards the other 2 LV phenotypes and survival free from the composite end point of all-cause mortality and heart transplantation.

resultsIn TTR-CA, the prevalence of preserved LV function was 32.0%, restriction was 56.1%, and systolic dysfunction was 11.9%. Among patients with preserved LV function, at the last evaluation, the conversion rate to restriction was 16.3% and to systolic dysfunction was 1.8%. The 3-year freedom from the composite end point was 75%, 61%, and 44%, respectively. In AL-CA, the prevalence of preserved LV function was 32.9%, restriction was 58.6%, and systolic dysfunction was 8.5%. Among patients with preserved LV function, at the last evaluation, the conversion rate to restriction was 12.9%, and to systolic dysfunction was none. The 3-year freedom from the composite end point was 46%, 32%, and 21%, respectively.

conclusionsRestriction was the most common presenting phenotype, while preserved LV function represented approximately one-third. The rate of progression from preserved LV function towards restriction was high, whereas it was limited towards systolic dysfunction. Although patients with preserved LV function presented the best event-free survival, considering all-cause mortality and heart transplantation, compared with restriction or systolic dysfunction, these phenotypes are not independent predictors of this composite end point.

Indexed as

Amyloid Neuropathies, FamilialCardiomyopathiesHeart FailureImmunoglobulin Light-chain AmyloidosisPrealbuminVentricular Dysfunction, LeftVentricular Function, LeftAgedFemaleHeart TransplantationHumansMaleMiddle AgedPhenotypePrevalencePrognosisPrealbuminTTR protein, humanamyloidosisglomerular filtration rateheart failurephenotypestroke volume

Identifiers

PMID41732853
PMCPMC12986034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.